122 related articles for article (PubMed ID: 17112849)
1. Tolerability of enteric-coated mycophenolate sodium to 1 year in combination with cyclosporine and corticosteroids in renal transplant recipients.
Rostaing L; Mourad G; Kamar N; Garrigue V; Karras A; Lefrançois N; Charpentier B; Bourbigot B; Pouteil-Noble C; Bayle F; Lebranchu Y; Berthoux F; Le Meur Y; Kessler M; Moulin B; Ducloux D; Delahousse M; Lang P; Merville P; Chaouche-Teyara K; Legendre C;
Transplant Proc; 2006 Nov; 38(9):2860-3. PubMed ID: 17112849
[TBL] [Abstract][Full Text] [Related]
2. Renal function with delayed or immediate cyclosporine microemulsion in combination with enteric-coated mycophenolate sodium and steroids: results of follow up to 30 months post-transplant.
Mourad G; Karras A; Kamar N; Garrigue V; Legendre C; Lefrançois N; Charpentier B; Bourbigot B; Pouteil-Noble C; Bayle F; Lebranchu Y; Mariat C; Le Meur Y; Kessler M; Moulin B; Ducloux D; Delahousse M; Lang P; Merville P; Chaouche-Teyara K; Rostaing L;
Clin Transplant; 2007; 21(3):295-300. PubMed ID: 17488375
[TBL] [Abstract][Full Text] [Related]
3. Use of enteric-coated mycophenolate sodium in de novo renal transplant recipients with high incidence of delayed graft function.
Schiavelli R; Gaite L; Agost Carreno C; Baran M; Novoa P; Massari P; Otero AB; Piulats E
Transplant Proc; 2006 Apr; 38(3):905-8. PubMed ID: 16647505
[TBL] [Abstract][Full Text] [Related]
4. Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patients.
Salvadori M; Holzer H; Civati G; Sollinger H; Lien B; Tomlanovich S; Bertoni E; Seifu Y; Marrast AC;
Clin Nephrol; 2006 Aug; 66(2):112-9. PubMed ID: 16939067
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of enteric-coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials.
Pietruck F; Budde K; Salvadori M; Sollinger H; Bourbigot B; Gentil MA; Oppenheimer F
Clin Transplant; 2007; 21(1):117-25. PubMed ID: 17302600
[TBL] [Abstract][Full Text] [Related]
6. Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine.
Nashan B; Suwelack B; Ivens K; Arns W; Lhotta K; Bourbigot B; Budde K; Fischer W; Pietruck F;
Transplant Proc; 2006 Nov; 38(9):2856-9. PubMed ID: 17112848
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12-month multicenter, open-label, prospective studies.
Legendre C; Cohen D; Zeier M; Rostaing L; Budde K
Transplant Proc; 2007 Jun; 39(5):1386-91. PubMed ID: 17580145
[TBL] [Abstract][Full Text] [Related]
8. Results of a 6-month, multicenter, open-label, prospective study concerning efficacy and safety of mycophenolate sodium in de novo kidney transplant recipients.
Wyzgał J; Niemczyk M; Ziółkowski J; Durlik M; Wiecek A
Transplant Proc; 2007 Nov; 39(9):2730-2. PubMed ID: 18021971
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of enteric-coated mycophenolate sodium (myfortic) in de novo renal transplant recipients: results of a 12-month multicenter, open-label, prospective study.
Vogt B; Antoniadis A; Klinger M; Vitko S
Transplant Proc; 2006 Jun; 38(5):1301-6. PubMed ID: 16797288
[TBL] [Abstract][Full Text] [Related]
10. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant patients: preliminary results from the myfortic prospective multicenter study.
Nashan B; Ivens K; Suwelack B; Arns W; Abbud Filho M; ;
Transplant Proc; 2004 Mar; 36(2 Suppl):521S-523S. PubMed ID: 15041400
[TBL] [Abstract][Full Text] [Related]
11. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
Budde K; Glander P; Diekmann F; Dragun D; Waiser J; Fritsche L; Neumayer HH
Transplant Proc; 2004 Mar; 36(2 Suppl):524S-527S. PubMed ID: 15041401
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients.
Kamar N; Rostaing L; Cassuto E; Villemain F; Moal MC; Ladrière M; Barrou B; Ducloux D; Chaouche K; Quéré S; Di Giambattista F; Be F
Clin Nephrol; 2012 Feb; 77(2):126-36. PubMed ID: 22257543
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of enteric-coated mycophenolate sodium in de novo and maintenance renal transplant patients.
Nart A; Sipahi S; Aykas A; Uslu A; Hoşcoşkun C; Toz H
Transplant Proc; 2008; 40(1):189-92. PubMed ID: 18261583
[TBL] [Abstract][Full Text] [Related]
14. Report of the experience with enteric-coated sodium mycophenolate in a de novo population of kidney transplant recipients at high risk for delayed graft function.
Novoa P; Rodríguez L; Gutiérrez L
Transplant Proc; 2007 Apr; 39(3):600-1. PubMed ID: 17445554
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic).
Budde K; Knoll G; Curtis J; Chan L; Pohanka E; Gentil M; Seifu Y; Marrast AC; Neumayer HH;
Clin Nephrol; 2006 Aug; 66(2):103-11. PubMed ID: 16939066
[TBL] [Abstract][Full Text] [Related]
16. Enteric-coated mycophenolate sodium in combination with full dose or reduced dose cyclosporine, basiliximab and corticosteroids in Australian de novo kidney transplant patients.
Chadban S; Eris J; Russ G; Campbell S; Chapman J; Pussell B; Trevillian P; Ierino F; Thomson N; Hutchison B; Irish A; Woodcock C; Kurstjens N; Walker R;
Nephrology (Carlton); 2013 Jan; 18(1):63-70. PubMed ID: 23110508
[TBL] [Abstract][Full Text] [Related]
17. Early experience with enteric-coated mycophenolate sodium in de novo kidney transplant recipients.
Chang HR; Lin CC; Lian JD
Transplant Proc; 2005 Jun; 37(5):2066-8. PubMed ID: 15964340
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
Bilodeau JF; Montambault P; Wolff JL; Lemire J; Masse M
Transplant Proc; 2009 Nov; 41(9):3683-9. PubMed ID: 19917367
[TBL] [Abstract][Full Text] [Related]
19. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.
Massari P; Duro-Garcia V; Girón F; Hernández E; Juárez F; Castro C; Toledo M;
Transplant Proc; 2005 Mar; 37(2):916-9. PubMed ID: 15848574
[TBL] [Abstract][Full Text] [Related]
20. Tolerance of enteric-coated mycophenolate sodium in combination with calcineurin inhibitor in kidney transplant recipients: Polish experience.
Gozdowska J; Urbanowicz AL; Galazka Z; Chmura A; Durlik M
Transplant Proc; 2011 Oct; 43(8):2946-9. PubMed ID: 21996197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
